Physician profile
Lori Fiessinger
NPI 1578982773
$2,162.72
in general payments reported to CMS, 2019-2025
20 companies · $597 in 2025
The $597 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.72 · 2022: $124 · 2023: $664 · 2024: $761 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,678 · Education: $344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,678.10 |
| Education | $343.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $618.76 | 2023-2025 | Tremfya, Simponi, Simponi Aria |
| Lilly USA, LLC | $219.63 | 2023-2025 | Ebglyss, Olumiant, Taltz |
| Amgen INC. | $190.10 | 2022-2025 | Otezla, Otezla |
| Genzyme Corporation | $176.13 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $160.91 | 2023-2025 | |
| Galderma Laboratories, L.P. | $112.51 | 2022-2025 | Aklief, Oracea, Nemluvio |
| Abbvie INC. | $96.35 | 2024 | |
| Incyte Corporation | $89.96 | 2023-2025 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.16 | 2023-2024 | Spevigo |
| Ucb, INC. | $65.81 | 2024-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $58.69 | 2023-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $50.94 | 2023-2025 | Adbry |
| Merz North America, INC. | $47.90 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $42.34 | 2023 | Blu-U, Ilumya |
| E.R. Squibb & Sons, L.L.C. | $38.18 | 2023-2024 | Sotyktu |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $28.50 | 2024-2025 | Hadlima |
| Biofrontera INC. | $25.85 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Botanix Sb INC | $24.80 | 2025 | Sofdra |
| Almirall LLC | $18.17 | 2024 | Seysara |
| Strata Skin Sciences, INC. | $17.03 | 2023 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Fiessinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.